Log In Sign up
The largest database of trusted experimental protocols

Fitc anti cd107a

Manufactured by BioLegend
Visit Supplier
Sourced in United States

FITC anti-CD107a is a flow cytometry antibody that binds to the CD107a (LAMP-1) surface marker. CD107a is a lysosome-associated membrane protein that is expressed on the cell surface during degranulation, making it a useful marker for evaluating cytotoxic cell activity.

Automatically generated - may contain errors

Lab products found in correlation

Ionomycin stimulations, by BD (2 mentions) Golgiplug golgistop, by BD (2 mentions) Bv711 anti cd62l, by BioLegend (2 mentions) Af700 anti cd44, by BioLegend (2 mentions) Cytoperm cytowash kit, by BD (2 mentions) Bv650 anti tnfα, by BioLegend (2 mentions) Pe cy7 anti il 2, by BioLegend (2 mentions) Anti ifn γ apc, by BioLegend (2 mentions) Pe cy5 anti cd3, by BioLegend (2 mentions) Anti cd8 apc cy7, by BioLegend (2 mentions) Anti cd4 bv510, by BioLegend (2 mentions) Lsrii flow cytometer, by BD (2 mentions) Facsdiva 6, by BD (1 mentions) Protein transport inhibitor, by Thermo Fisher Scientific (1 mentions) Zombie red, by BioLegend (1 mentions) Ficoll paque plus, by GE Healthcare (1 mentions) Ionomycin, by Merck Group (1 mentions) Protein transport inhibitor, by BD (1 mentions) Cd3 apc cy7, by BioLegend (1 mentions) Cd4 apc, by BioLegend (1 mentions)

Spelling variants of this product

Anti-CD107a (26 citations) FITC anti-human CD107a (4 citations) CD107a FITC (3 citations) FITC conjugated anti-CD107a (3 citations) Anti–CD107a-FITC antibody (2 citations) FITC-conjugated anti-mouse CD107a MAb (2 citations) Anti-CD107a FITC monoclonal antibody (2 citations) FITC-labeled anti-human CD107a mAb clone H4A3 (2 citations) FITC-labeled anti-CD107a antibody (2 citations)

6 protocols using fitc anti cd107a

1

Intracellular Cytokine Profiling of Splenocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
For intracellular cytokine staining, 2 × 106 splenocytes were stimulated in the presence of protein transport inhibitor, GolgiStopTM GolgiPlugTM (BD Bioscience) with the same peptide pools as the ELISpots. Media alone and phorbol 12-myristate 13-acetate (PMA) and ionomycin stimulations (BD Bioscience) were used as negative and positive controls respectively. To test for degranulation of cells, FITC anti-CD107a (Biolegend) antibody was also added during stimulation. After 6 h, cells were washed and stained with LIVE/DEAD violet. Surface staining was then added containing BV510 anti-CD4, APC-Cy7 anti-CD8, BV711 anti-CD62L, and AF700 anti-CD44 (Biolegend). After 30 min incubation, cells were spun, washed, and fixed using the CytoPerm CytoWash kit following the manufacturer’s protocol (BD Bioscience). Intracellular staining was then prepared using APC anti-IFNγ, BV650 anti-TNFα, PE-Cy7 anti-IL-2, and PE-Cy5 anti-CD3 (Biolegend). All data were collected on a modified LSRII flow cytometer (BD Bioscience) with FACS DIVA 6.0 GUI followed by analysis with FlowJo software 9.0 (BD Bioscience).
Xu Z., Walker S., Wise M.C., Chokkalingam N., Purwar M., Moore A., Tello-Ruiz E., Wu Y., Majumdar S., Konrath K.M., Kulkarni A., Tursi N.J., Zaidi F.I., Reuschel E.L., Patel I., Obeirne A., Du J., Schultheis K., Gites L., Smith T., Mendoza J., Broderick K.E., Humeau L., Pallesen J., Weiner D.B, & Kulp D.W. (2022). Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer. Nature Communications, 13, 695.
+ Open protocol
+ Expand
2

PBMC Activation and Cytokine Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells (PBMC) were isolated over a density
gradient using Ficoll-Paque Plus (GE Healthcare). Isolated PBMC were washed in
phosphate buffered saline and incubated for 5 hours with FITC-anti-CD107a
(Biolegend) and Protein Transport Inhibitor (eBioscience) in RPMI1640 as above
with or without 50ng/mL phorbol 12-myristate 13-acetate (PMA), and 1μ
g/mL ionomycin (Sigma-Aldrich). After incubation the cells were washed and
stained with APC-Cy7-CD8 (clone HIT8a), PerCP-Cy5.5-CD19 (clone HIB19),
PerCP-Cy5.5-HLA-DR (clone L243), and Zombie Red (Biolegend). The cells were then
washed, fixed and permeabilized using the BD Biosience Cytoperm/Cytofix kit per
the manufacture’s protocol, and stained with BV421-IFNγ (clone
4S.B3, Biolegend). Flow cytometric analysis was analyzed as above. A total of 4
patients from the Ipilimumab only group and 3 from Ipilimumab plus ATRA were
included in this analysis. There was insufficient sample from one of the
Ipilimumab plus ATRA treated patients and the T cell response assay was not
performed.
Tobin R.P., Jordan K.R., Robinson W.A., Davis D., Borges V.F., Gonzalez R., Lewis K.D, & McCarter M.D. (2018). Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.. International immunopharmacology, 63, 282-291.
+ Open protocol
+ Expand
3

Intracellular Cytokine Staining of Splenocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
For intracellular cytokine staining, 2x10 6 splenocytes were stimulated in the presence of protein transport inhibitor, GolgiStop TM GolgiPlug TM (BD Bioscience) with the same peptide pools as the ELISpots.
Media alone and phorbol 12-myristate 13-acetate (PMA) and ionomycin stimulations (BD Bioscience) were used as negative and positive controls respectively. To test for degranulation of cells, FITC anti-CD107a (Biolegend) antibody was also added during stimulation. After 6hrs, cells were washed and stained with LIVE/DEAD violet. Surface staining was then added containing BV510 anti-CD4, APC-Cy7 anti-CD8, BV711 anti-CD62L and AF700 anti-CD44 (Biolegend). After 30 minutes incubation, cells were spun, washed, and fixed using the CytoPerm CytoWash kit following manufacturer's protocol (BD Bioscience).
Intracellular staining was then prepared using APC anti-IFNγ, BV650 anti-TNFα, PE-Cy7 anti-IL2, and PE-Cy5 anti-CD3 (Biolegend). All data was collected on a modified LSRII flow cytometer (BD Bioscience) followed by analysis with FlowJo software (BD Bioscience).
Xu Z., Walker S.N., Wise M.C., Chokkalingam N., Purwar M., Moore A., Tello‐Ruiz E., Wu Y., Majumdar S., Zaidi F.I., Reuschel E.L., Patel I., Obeirne A., Du J., Schultheis K., Gites L., Smith T.R., Mendoza J., Broderick K.E., Humeau L., Pallesen J., Weiner D.B., & Kulp D.W. (2021). Structural identification of neutralizing antibodies induced by nucleic acid encoded native-like trimer.
+ Open protocol
+ Expand
4

Quantifying CAR-T Cell Cytotoxicity

Check if the same lab product or an alternative is used in the 5 most similar protocols
An E:T ratio of 1:1 was used when co‐culturing CD44v6 CAR‐T (or NT) cells with target cells in complete RPMI 1640 media containing anti‐CD107a‐FITC (Biolegend, USA) and protein transport inhibitor (BD Bioscience, USA) for 4 h. CD3‐APC/Cy7(Biolegend, USA), CD4‐APC (Biolegend, USA) and CD8‐BV605 (BD Bioscience, USA) were used to stain the harvested cells.
Tang L., Huang H., Tang Y., Li Q., Wang J., Li D., Zhong Z., Zou P., You Y., Cao Y., Kong Y., Guo A., Zhou S., Li H., Meng F., Xiao Y, & Zhu X. (2022). CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations. Clinical and Translational Medicine, 12(9), e1043.
+ Open protocol
+ Expand
5

Activated T cell Immunophenotyping in Mice

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Adequate single cells were isolated from the spleen, peripheral blood, colon adjacent tissues, and adenoma tissues of mice. These cells were incubated with the appropriate surface antibodies: anti-CD45-PE/Cy7 (Biolegend, Cat# 103113), anti-CD3-PE/Cy7 (Biolegend, Cat# 100219), anti-CD4-FITC (Invitrogen, 11-0041-85), anti-CD8a-APC (Invitrogen, 47-0081-82), anti-CD11b-FITC (Biolegend, Cat# 101206), anti-Gr-1-PE (Biolegend, Cat# 108408), anti-CD107a-FITC (Biolegend, Cat# 121605), and anti-CD137-APC (Biolegend, Cat# 106109). For intracellular staining, cells were treated with the Fixation/Permeabilization solution (Invitrogen, 00-5223-56) overnight at 4 °C before incubating with intracellular antibodies: anti-IFNγ-PE (Biolegend, Cat# 163503). CD4+ T cells were defined as CD45+CD4+CD8a−; CD8+ T cells were defined as CD45+CD4−CD8a+; activated CD4+ T cells were defined as CD3+CD4+CD137+IFNγ+; and activated CD8+ T cells were defined as CD3+CD8a+CD107a+IFNγ+ [23 (link),24 (link)]. Data acquisition was performed on an Accuri C6 Plus and analyzed using FlowJo (RRID:SCR_008520).
Guo B., Zheng Y., Fan Y., Yang Y., Wang Y., Qin L., An Y., Xu X., Zhang X., Sun G., Dou H., Shao C., Gong Y., Jiang B, & Hu H. (2024). Enhanced ApcMin/+ adenoma formation after epithelial CUL4B deletion by recruitment of myeloid-derived suppressor cells. Neoplasia (New York, N.Y.), 53, 101005.
+ Open protocol
+ Expand
6

Comprehensive PBMC Cytokine Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
About 150,000 peripheral blood mononuclear cells (PBMCs) per well were stimulated in a 96-well plate with peptides (2.5 ng/ml), 1 μg/ml anti-CD28, anti-CD49d, and anti-CD107a FITC (BioLegend) for 6 hr. After 30 min, 5 μg/ml Brefeldin A and 1× Monensin (BioLegend) were added. The positive control contained 2.5 ng/ml PMA and 25 ng/ml ionomycin, and the negative cells and CD28/CD49d. Cells were washed and stained with LIVE/DEAD Fixable Violet stain (Invitrogen), fixed, and permeabilized with BD Fix/Perm solution (BD) and stained with a mix of fluorochrome-conjugated antibodies: CD3 EDC, CD8 PerCP (BD), interleukin (IL)-2 PE, IFN-γ, Pe-Cy7, and tumor necrosis factor (TNF)-α APC (BioLegend). Unstained and singly stained cells were used as controls to calculate compensation. The cell fluorescence intensities were acquired on a Cyan ADP Cytometer (Beckman Coulter) and analyzed with Summit software (Dako).
Tenzer S., Crawford H., Pymm P., Gifford R., Sreenu V.B., Weimershaus M., de Oliveira T., Burgevin A., Gerstoft J., Akkad N., Lunn D., Fugger L., Bell J., Schild H., van Endert P, & Iversen A.K. (2014). HIV-1 Adaptation to Antigen Processing Results in Population-Level Immune Evasion and Affects Subtype Diversification. Cell Reports, 7(2), 448-463.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!